ArticleTobacco control2018
Revolution or redux? Assessing IQOS through a precursor product.
Article in Tobacco control, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Heated tobacco products for smoking cessation and reducing smoking prevalence.The Cochrane database of systematic reviews · 2022Pooled it
- Effect of a hypothetical modified risk tobacco product claim on heated tobacco product use intention and perceptions in young adults.Tobacco control · 2023Trial
- Long-term health risks of e-cigarettes after smoking cessation.Nature medicine · 2026Article
- More than a "characterizing flavor": Menthol at subliminal levels in tobacco products.Drug and alcohol dependence · 2024Review
- Cerebral Cortical Vasodilation via Nicotinic Receptors by Heated Tobacco Product Aerosol Extract in Rats.Journal of vascular research · 2024Article
- Heated tobacco products and cigarette marketing in nightclubs in Gdansk, Poland: A mixed-methods analysis.Tobacco prevention & cessation · 2024Article
- How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Article
- Corporate communication of the relative health risks of IQOS through a webchat service.Tobacco control · 2023Article
- Effect of Heating Temperature on Ammonia Emission in the Mainstream Aerosols from Heated Tobacco Products.Toxics · 2022Article
- Tobacco industry messaging around harm: Narrative framing in PMI and BAT press releases and annual reports 2011 to 2021.Frontiers in public health · 2022Article
- Unboxed: US Young Adult Tobacco Users' Responses to a New Heated Tobacco Product.International journal of environmental research and public health · 2020Article
- A Method for Comparing the Impact on Carcinogenicity of Tobacco Products: A Case Study on Heated Tobacco Versus Cigarettes.Risk analysis : an official publication of the Society for Risk Analysis · 2020Article
- Analysis of FDA's IQOS marketing authorisation and its policy impacts.Tobacco control · 2020Article
- Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.Tobacco control · 2019Article
- Tobacco company strategies to identify and promote the benefits of nicotine.Tobacco control · 2019Article
- Heated tobacco products: another tobacco industry global strategy to slow progress in tobacco control.Tobacco control · 2018Article
- Heated tobacco product regulation under US law and the FCTC.Tobacco control · 2018Article
- Heated tobacco products: the example of IQOS.Tobacco control · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPhilip Morris International (PMI) currently claims that its heated tobacco product, IQOS, reduces health risk by reducing users' exposure to harmful and potentially harmful constituents present in tobacco smoke. Given the tobacco industry's long history of misrepresenting and obfuscating research, independent assessment of PMI's claims is important. Analysis of Accord, a failed but strikingly similar precursor to IQOS, may help contextualise PMI's claims in its Modified Risk Tobacco Product (MRTP) application.
methodsWe analysed previously secret internal Philip Morris (PM) and PMI documents, public communications and MRTP application.
resultsPM marketed Accord as a 'cleaner' tobacco product in an attempt to address smokers' growing health concerns without making explicit health claims. While PM communications asserted that Accord reduced users' exposure to harmful constituents, company scientists and executives consistently stressed to both regulators and the public that such reductions did not render Accord safer. IQOS's design and marketing are similar to Accord's. On the basis of aerosol chemistry data, IQOS reduces user exposure to some compounds compared with Accord but raises them for others. DISCUSSION: IQOS appears to be a variant of Accord without consistent improvements in exposure to aerosol toxic compounds. In contrast to PM's past claims for Accord, PMI now claims in its MRTP application that IQOS reduces health risk. This shift in stance is likely not the result of any toxicological difference between Accord and IQOS, but rather a change in the social and regulatory landscape permitting these claims.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.